ClinicalTrials.gov
public full text
Public Domain
sCD163 in PBC Patients - Assessment of Disease Severity and Prognosis
Primary biliary cholangitis (PBC) is an autoimmune chronic liver disease, characterised by destruction of the small intrahepatic bile ducts. sCD163 is a macrophage activation marker shedded into plasma by macrophages in the liver. sMR is a soluble mannose receptor. The investigators want to investigate whether sCD163 and sMR correlate with disease severity in patients with PBC, and whether sCD163 and sMR can predict short term disease progression, changes in quality of life and death in these patients.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Identification of Inflammatory and Fibrotic Biomarkers in PBC and NAFLD Patients#868209
- Study on Clinical and Pathological Features of Primary Biliary Cholangitis and Risk Factors Related to Disease Progression#1057176
- Étude de l’inhibition pharmacologique de RIPK1 dans la cholangite sclérosante primitive#1166449
- Austrian PBC Registry#852936
- Effect of Cyanobacteria Patients With Chronic Hepatitis B Surface Antigen Quantitative Concentration#841991
Record · ID 1103712
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive